Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jun;24(7):720-9.
doi: 10.1177/0961203314563818. Epub 2014 Dec 15.

Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

J M Pego-Reigosa  1 , Í Rúa-Figueroa  2 , F J López-Longo  3 , M Galindo-Izquierdo  4 , J Calvo-Alén  5 , A Olivé-Marqués  6 , V del Campo  7 , M J García-Yébenes  8 , E Loza-Santamaría  8 , R Blanco  9 , R Melero-González  10 , P Vela-Casasempere  11 , T Otón-Sánchez  12 , E Tomero-Muriel  13 , E Uriarte-Isacelaya  14 , M C Fito-Manteca  15 , M Freire-González  16 , J Narváez  17 , A Fernández-Nebro  18 , A Zea-Mendoza  19 , J Rosas  20 ; RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)
Collaborators, Affiliations
Clinical Trial

Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus

J M Pego-Reigosa et al. Lupus. 2015 Jun.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Lupus. 2015 Aug;24(9):1008. doi: 10.1177/0961203315592751. Lupus. 2015. PMID: 26195503 No abstract available.

Abstract

Objectives: The objectives of this paper are to study the impact of disease activity in a large cohort of patients with systemic lupus erythematosus (SLE) and estimate the rate of response to therapies.

Methods: We conducted a nationwide, retrospective, multicenter, cross-sectional cohort study of 3658 SLE patients. Data on demographics, disease characteristics: activity (SELENA-SLEDAI), damage, severity, hospitalizations and therapies were collected. Factors associated with refractory disease were identified by logistic regression.

Results: A total of 3658 patients (90% female; median SLE duration (interquartile range): 10.4 years (5.3-17.1)) were included. At the time of their last evaluation, 14.7% of the patients had moderate-severe SLE (SELENA-SLEDAI score ≥6). There were 1954 (53.4%) patients who were hospitalized for activity at least once over the course of the disease. At some stage, 84.6% and 78.8% of the patients received glucocorticoids and antimalarials, respectively, and 51.3% of the patients received at least one immunosuppressant. Owing to either toxicity or ineffectiveness, cyclophosphamide was withdrawn in 21.5% of the cases, mycophenolate mofetil in 24.9%, azathioprine in 40.2% and methotrexate in 46.8%. At some stage, 7.3% of the patients received at least one biologic. A total of 898 (24.5%) patients had refractory SLE at some stage. Renal, neuropsychiatric, vasculitic, hematological and musculoskeletal involvement, a younger age at diagnosis and male gender were associated with refractory disease.

Conclusions: A significant percentage of patients have moderately-to-severely active SLE at some stage. Disease activity has a big impact in terms of need for treatment and cause of hospitalization. The effectiveness of the standard therapies for reducing disease activity is clearly insufficient. Some clinical features are associated with refractory SLE.

Keywords: Systemic lupus erythematosus; disease activity; treatment.

PubMed Disclaimer

Publication types

LinkOut - more resources